Welcome to our dedicated page for Enveric Biosciences SEC filings (Ticker: ENVB), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Enveric Biosciences, Inc. (NASDAQ: ENVB) SEC filings page on Stock Titan centralizes the company’s regulatory disclosures from the U.S. Securities and Exchange Commission. Enveric is a biotechnology company focused on small-molecule neuroplastogenic therapeutics for psychiatric and neurological disorders, and its filings provide detailed information on financing transactions, listing status, governance matters, and risk factors as described by the company.
Investors researching ENVB can use this page to access current reports on Form 8‑K, which Enveric has filed in connection with warrant exercise inducement agreements, private placements of new warrant series, and related use of proceeds for product development, working capital, and general corporate purposes. Other 8‑K filings address Nasdaq listing qualifications, including notices regarding stockholders’ equity requirements, minimum bid price deficiencies, and the implementation of a 1‑for‑12 reverse stock split approved by stockholders and effected through a certificate of amendment.
The filings feed also includes proxy materials such as the definitive proxy statement on Schedule DEF 14A, where Enveric outlines proposals for stockholder approval. These have included authorizations for share issuances related to warrants, reverse stock split ranges, and increases in authorized common stock. Voting results for special meetings and annual meetings are reported in subsequent 8‑K filings, giving readers transparency into stockholder decisions.
Through periodic reports referenced in Enveric’s press releases, such as its Annual Report on Form 10‑K and Quarterly Reports on Form 10‑Q, the company discusses its business, pipeline, patent estate, financial condition, and risk factors. On Stock Titan, users can quickly locate these documents and use AI-powered summaries to interpret complex sections, including descriptions of EB‑003 and other neuroplastogenic programs, capital structure details, and discussions of Nasdaq compliance.
In addition, this page provides access to information about unregistered sales of equity securities, warrant terms, and changes to the company’s charter reported in SEC filings. AI-generated highlights help readers identify key terms—such as exercise prices, expiration dates, and conditions for new warrant series—without manually parsing every exhibit. For those tracking ENVB, the SEC filings page offers a structured way to review how Enveric presents its strategy, financing activities, and governance actions in official regulatory documents.
Enveric Biosciences, Inc. is registering the offer and resale of up to 6,822,225 shares of its common stock.
The registration covers resale by selling stockholders of (i) 98,000 shares issued in a private placement, (ii) 2,124,223 shares issuable upon exercise of pre-funded warrants, (iii) 2,222,223 shares issuable upon exercise of Series I Warrants, (iv) 2,222,223 shares issuable upon exercise of Series J Warrants, and (v) 155,556 shares issuable upon exercise of placement agent warrants. The company will receive no proceeds from resales; the selling holders may sell from time to time at prevailing market or negotiated prices. The registration relates to resale rights granted in connection with a Private Placement and includes customary beneficial ownership limits of 4.99% and 9.99% on warrant exercise; sales are subject to the plan of distribution described in the prospectus.
Enveric Biosciences, Inc. entered into a private placement financing with institutional investors, raising approximately $5.0 million in gross proceeds. The company agreed to sell 2,222,223 shares of common stock, or pre-funded warrants in lieu of shares, together with Series I and short-term Series J warrants, at a purchase price of $2.25 per share (or pre-funded warrant) and accompanying warrants.
The accompanying warrants have an exercise price of $2.00 per share and are exercisable immediately. Series I warrants will expire five years after the effective date of a resale registration statement, while Series J warrants will expire eighteen months after that date. If all Series I and Series J warrants are exercised for cash, Enveric could receive up to an additional $8.9 million in gross proceeds. The company plans to use net proceeds for product development, working capital, and general corporate purposes.
Enveric Biosciences, Inc. has called its 2026 annual stockholder meeting for May 28, 2026 at 10:00 a.m. Eastern Time, to be held exclusively online via live webcast. Stockholders of record as of March 30, 2026, when 1,887,535 shares of common stock were outstanding, may vote.
Investors are asked to elect six directors, cast an advisory “say‑on‑pay” vote on executive compensation, and extend prior approvals that give the board flexibility to effect a reverse stock split within a specified range and to increase authorized common shares from 100,000,000 to 5,000,000,000. The agenda also includes ratifying CBIZ CPAs P.C. as independent auditor for 2026 and approving potential adjournment to solicit additional proxies if needed.
The proxy details online and telephone voting procedures, broker voting rules, and how quorum and vote thresholds are calculated. It also outlines the company’s governance structure, board committees, cybersecurity oversight, and 2025 executive pay, including salary and stock‑based awards for the CEO, Chief Innovation Officer and CFO.
Enveric Biosciences, Inc. is soliciting proxies for its 2026 virtual Annual Meeting of Stockholders to be held via webcast. The board asks stockholders to vote on electing six directors and on proposals that include an extension to effect a reverse stock split at ratios between 1-for-5 and 1-for-50 and an extension to increase authorized common stock from 100,000,000 to 5,000,000,000 shares. Other proposals include advisory approval of executive compensation, ratification of CBIZ CPAs P.C. as auditor, and an adjournment proposal.
Enveric Biosciences is a Delaware-based biotechnology company developing next‑generation, non‑hallucinogenic neuroplastogenic drugs for psychiatric and neurological disorders. Its lead candidate, EB‑003, a DMT‑derived compound from the EVM301 Series, is in preclinical development with IND‑enabling studies planned.
The company also maintains a large psychedelic‑inspired IP library (Psybrary™) and has out‑licensed certain cannabinoid and psychedelic assets. As of June 30, 2025, non‑affiliate equity value was about $3.6 million, and the auditor has raised substantial doubt about Enveric’s ability to continue as a going concern due to recurring losses and funding needs.
Enveric Biosciences reported a net loss attributable to stockholders of $4.0 million for the quarter ended December 31, 2025, compared with a net loss of $3.2 million a year earlier. Basic and diluted loss per share was $6.12 for the quarter. The company ended 2025 with $4.7 million in cash and raised gross proceeds of $12.2 million during the year through offerings, including $4.9 million in the fourth quarter.
Subsequently, Enveric raised about $1.5 million in a registered direct offering in January 2026 and approximately $1.45 million via an at-the-market offering in February 2026. Operationally, the company advanced its lead candidate EB-003, a non-hallucinogenic neuroplastogen, by completing pre-IND dose range finding studies, achieving key manufacturing milestones, and receiving FDA feedback allowing streamlined plans for an IND submission ahead of a planned first-in-human Phase 1 trial. Enveric also strengthened its intellectual property around the EVM301 and EVM401 compound series, executed licensing agreements for cannabinoid-COX-2 conjugates, expanded a topical cannabinoid collaboration, and completed a 1-for-12 reverse stock split while relocating its headquarters to Cambridge, Massachusetts.
Enveric Biosciences filed a prospectus registering 680,620 shares of Common Stock. The registration covers up to 328,802 shares issuable upon exercise of Series G Warrants, up to 328,802 shares issuable upon exercise of Series H Warrants, and 23,016 shares issuable upon exercise of Placement Agent Warrants.
The prospectus states the Company will not receive proceeds from sales by the Selling Stockholders, but will receive net proceeds if the January 2026 Warrants are exercised for cash. The exercise prices are $4.16 for the Series G and H Warrants and $5.5125 for the Placement Agent Warrants. The document cites 1,390,335 shares outstanding as of February 4, 2026 and an assumed post‑exercise outstanding share count of 2,070,955 if all January 2026 Warrants are exercised. The prospectus notes a last reported Nasdaq sale price of $2.84 on February 4, 2026.
Enveric Biosciences, Inc. has filed an S-1 registering 680,620 shares of common stock underlying January 2026 warrants, including Series G, Series H and placement agent warrants issued in connection with a January 2026 registered direct offering and concurrent private placement.
The filing covers issuance of shares upon warrant exercise and their resale by selling stockholders. Enveric will not receive proceeds from stockholder resales, but would receive cash if the warrants are exercised at $4.16 per share for the Series G and H warrants and $5.5125 per share for the placement agent warrants, planned for product development, working capital and general corporate purposes.
The company focuses on non-hallucinogenic, neuroplastogenic small-molecule therapies, led by EB-003, and highlights significant risks, including substantial liquidity needs, going concern uncertainty, dependence on early-stage drug candidates, future dilution from equity financings and warrants, and high volatility in its Nasdaq-listed ENVB shares.